奥沙利铂联合卡培他滨二线治疗晚期胃癌临床疗效及对患者生活质量的影响

Clinical efficacy of oxaliplatin combined with capecitabine as second-line treatment for advanced gastric cancer and its influence on patients'quality of life

目的分析比较奥沙利铂+卡培他滨作为二线化疗方案治疗晚期胃癌的临床疗效及安全性。方法选择2016年3月~2019年2月收治的59例老年晚期胃癌患者为研究对象,根据治疗方法分为对照组30例与研究组29例,对照组治疗方案:200 mg/d亚叶酸钙静滴2 h,d1~5;750 mg/d 5-Fu,缓缓静滴8 h,d1~5;130 mg/m^(3)奥沙利铂,静滴2 h,d1;研究组治疗方案:130 mg/m^(3)奥沙利铂静滴2 h,d1;1000 mg/m^(2)卡培他滨,每天2次,口服,d1~14。比较两组临床疗效、生存质量、不良反应等。结果对照组临床总有效率为30.0%略低于研究组37.9%,比较差异无统计学意义(P>0.05)。治疗前,两组生活质量评估差异无统计学意义(P>0.05);治疗后,两组生活质量评分均明显升高,研究组生存质量评分明显高于对照组(P<0.05)。研究组治疗后不良反应发生情况明显轻于对照组(P<0.05)。结论奥沙利铂+卡培他滨二线治晚期胃癌疗效确切,不良反应发生率低,可改善患者生活质量。

Objective To analyze and compare the clinical efficacy and safety of oxaliplatin+capecitabine as second-line chemotherapy in the treatment of advanced gastric cancer.Methods A total of 59 elderly patients with advanced gastric cancer from March 2016 to February 2019 in people's Hospital of Pidu District of Chengdu were selected as the research objects.According to the treatment methods,they were divided into control group(n=30)and study group(n=29).The control group:200 mg/d calcium folinate intravenous drip for 2 h,d1~5;750 mg/d 5-Fu,slowly intravenous drip for 8 h,d1~5;130 mg/m^(3) oxaliplatin,intravenous drip for 2 h,d1;study group:130 mg/m^(3) oxaliplatin,intravenous drip for 2 h,d1;1000 mg/m^(2) capecitabine,twice a day,oral,d1~14.The clinical efficacy,quality of life and side effects were compared between the two groups.Results The clinical total effective rate of the control group was 30.0%,which was slightly lower than that of the study group(37.9%),and the difference was not statistically significant(P>0.05).Before treatment,there was no significant difference in quality of life between the two groups(P>0.05);after treatment,the scores of quality of life in both groups were significantly increased,and the score of quality of life in the study group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions in the study group was significantly lighter than that in the control group(P<0.05).Conclusion Axaliplatin+capecitabine as second-line treatment for advanced gastric cancer is effective,with low incidence of adverse reactions,which can improve the quality of life of patients.